Collaborative Pediatric Critical Care Research Network - Clinical Site

摘要-科罗拉多大学丹佛分校 随着我们参与合作儿科重症监护研究网络（CPCCRN）的这次迭代， 我们为一系列发现做出了贡献，这些发现增强了我们对疾病过程的理解， 许多潜在的有效治疗危重病和受伤的儿童，需要明确的评估 在临床试验阶段在儿科关键领域，仍然非常需要一个合作研究网络。 注意促进科学和技术发现迅速有效地转化为临床进展。 在进行临床试验时，接触适当的病人和获得专门知识必须与科学家和 实验室在科学进步的前沿在学科内和跨学科工作。大学 科罗拉多丹佛（ucd）和儿童医院科罗拉多（chco），我们有着悠久的成功历史， 合作的基础，转化和临床科学计划，重点是儿科危重病和损伤。 我们将为CPCCRN提供几个独特的优势领域，包括：1）一支独特的多学科团队 在心血管和心血管疾病的机制研究方面具有特定专业知识的合作研究人员， 肺部疾病，2）作为CPCCRN的临床研究中心，拥有经过验证的成功记录，3） 儿科临床试验执行，包括创新计划，以加强积极的研究文化， 临床工作人员和患者及家属的参与，4）7个州的集水区， 危重和受伤儿童，5）内部康复计划和广泛的门诊外展计划 能够为我们几乎所有的重症患者提供后续护理，6）与 儿童医院科罗拉多研究所和科罗拉多临床转化科学研究所提供 广泛的研究资源。我们的辅助站点，阿肯色州儿童医院（ACH）提供1）经验 与儿科临床试验的执行，包括在CPCCRN 2）提供护理之前成功的成员资格 向来自阿肯色州和四个州集水区的几乎所有重症儿童提供代表 机构发展奖（IDEA）州（历史上获得NIH支持的水平较低）， 他们在NIH使命中的独特人群（农村、马绍尔和医疗服务不足的社区），以及 4)与ACH研究所和阿肯色州临床转化科学大学建立了丰富的合作伙伴关系 奖提供全面的研究资源。利用这些资产，我们将增加捐款， CPCCRN通过严格的临床试验执行，创新的翻译， 和临床试验提案，参与CPCCRN领导委员会，并培训下一代 儿科重症监护研究人员。拟定的"脓毒症诱导的个性化免疫调节"试验 多器官功能障碍综合征"是一个令人难以置信的创新方法，超越了"一个治疗 为所有人"的范例，以个性化的治疗方法，将大大改善儿童的结果 败血症我们充满热情，并致力于参与这个项目与新的24个网站CPCCRN。

ABSTRACT – University of Colorado Denver With our participation in this iteration of the Collaborative Pediatric Critical Care Research Network (CPCCRN), we contributed to a series of discoveries that enhanced our understanding of disease processes and resulted in a multitude of potentially effective treatments for critically ill and injured children that require definitive evaluation in clinical trials. There continues to be tremendous need for a collaborative research network in pediatric critical care to facilitate the swift and effective translation of scientific and technologic discoveries into clinical advances. Access to appropriate patients and expertise in the execution of clinical trials must be linked to scientists and laboratories working within and across disciplines at the cutting edge of scientific advancement. At the University of Colorado Denver (UCD) and Children’s Hospital Colorado (CHCO), we have a long history of successful collaborative basic, translational, and clinical science programs focused on pediatric critical illness and injury. We will provide several unique areas of strength to the CPCCRN, including: 1) a distinctive multidisciplinary team of collaborative researchers with specific expertise in mechanistic investigations of cardiovascular and pulmonary diseases, 2) a proven and successful track record as a clinical site in CPCCRN, 3) expertise with pediatric clinical trials execution, including innovative programs to enhance positive research culture among clinical staff and participation among patients and families, 4) a 7-state catchment area with high volumes of critically ill and injured children, 5) an in-house rehabilitation program and extensive outpatient outreach program capable of providing follow-up care to nearly all our critically ill patients, and 6) a dynamic partnership with the Children’s Hospital Colorado Research Institute and Colorado Clinical Translational Science Institute to provide extensive research resources. Our ancillary site, Arkansas Children’s Hospital (ACH) provides 1) experience with pediatric clinical trials execution, including previous successful membership in CPCCRN 2) provision of care to nearly all of the critically ill children from the State of Arkansas and a 4-state catchment area, 3) representation of an Institutional Development Award (IDeA) state (historically received low levels of NIH support) and involving their unique populations (rural, Marshallese, and medically underserved communities) in the NIH mission, and 4) a rich partnership with the ACH Research Institute and University of Arkansas Clinical Translational Science Award to provide comprehensive research resources. Utilizing these assets, we will augment the contributions of CPCCRN to the care of critically ill children through rigorous clinical trial execution, innovative translational and clinical trial proposals, participation in CPCCRN leadership committees, and training the next generation of pediatric critical care researchers. The proposed trial of “Personalized Immunomodulation in Sepsis induced Multiple Organ Dysfunction Syndrome” is an incredibly innovative approach that moves beyond a “one therapy for all” paradigm to an individualized therapeutic approach that will dramatically improve outcomes for children with sepsis. We are enthusiastic and committed to participate in this project with the new 24-site CPCCRN.